Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
American Journal of Hematology|May 13, 2022
Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasmsMithun Vinod Shah, Rakchha Chhetri, Ruchita Dholakia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2020
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive ChemotherapyChong Chyn Chua, Andrew W Roberts, John Reynolds, et al.
Blood|September 24, 2024
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemiaSun Loo, Nicola Potter, Adam Ivey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2024
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)Ing Soo Tiong, Devendra K Hiwase, Emad Abro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2019
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II StudyAndrew H Wei, Stephen A Strickland, Jing-Zhou Hou, et al.
Blood|June 4, 2026
ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid LeukemiaChristopher S Hourigan, Lisanne Beugelink, Jad Othman, et al.
The Lancet. Haematology|July 22, 2024
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trialMatteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, et al.
Leukemia|September 15, 2018
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemiaDonia M Moujalled, Giovanna Pomilio, Corina Ghiurau, et al.
Blood Advances|February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Lancet (London, England)|June 13, 2023
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trialUwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, et al.
Pageof 4